IDDF2021-ABS-0102 Retrospective analysis of characteristics, indications and outcomes of ercp in a tertiary referral center of Saudi Arabia

Abstract

SGLT2i showed the greatest reduction in BMI, being superior to sulfonylurea (MD: -1.67, CI: -3.09 to -0.25) and standard of care (MD: 3.45, CI: 1.24 to 5.66). SGLT2i showed the greatest reduction of LDL and TG and the greatest increase of HDL. Conclusions SGLT2i, GLP-1RA and PPARg agonists are viable choices for the management of NAFLD in diabetic patients. SGLT2i was found to be most efficacious for fibrosis and BMI reduction, GlP1-RA for steatosis reduction and PPARg agonists for lipid modulation and should be considered over sulfonylurea for second-line therapy.